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Background: Several synthetic 
glycosphingolipids have been tested to 
determine their capacity to activate Type I 
NKT cells. 
Results: While the TCR binds with high 
affinity to all CD1d-presented glycolipids, 
only a few activate Type I NKT cells in vivo.  
Conclusions: TCR binding affinity does not 
necessarily predict antigenicity in vivo.  
Significance: The prediction of the 
therapeutic efficacy of Type I NKT cell 
antigens requires complementary assays. 
 
ABSTRACT 
 The ability of different 
glycosphingolipids (GSLs) to activate Type 
I Natural Killer T cells (NKT cells) has 
been known for two decades. The possible 
therapeutic use of these GSLs has been 
studied in many ways, however studies in 
which the efficacy of promising GSLs is 
compared under identical conditions are 
missing. Here we compare five unique 
GSLs structurally derived from α-
galactosylceramide (αGalCer). We 
employed biophysical and biological assays, 
as well as X-ray crystallography to study 
the impact of the chemical modifications of 
the antigen on Type I NKT cell activation. 
While all glycolipids are bound by the TCR 
of Type I NKT cells in real-time binding 
assays with high affinity, only a few activate 
Type I NKT cells in in vivo or in vitro 
experiments. The differences in biological 
responses are likely a result of different 
pharmacokinetic properties of each lipid, 
which carry modifications at different parts 
of the molecule. Our results indicate a need 
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to perform a variety of assays to ascertain 
the therapeutic potential of Type I NKT cell 
GSL activators.   
   
 
Natural Killer T (NKT) cells are a unique 
population of T lymphocytes with the capacity 
to impact a wide array of functions of the 
immune system, ranging from protection 
against infections to responses to tumors and 
the regulation of autoimmunity (1,2). These 
cells accomplish this feat through their ability 
to secrete T helper type 1 (Th1) and T helper 
type 2 (Th2) cytokines, most notably IFN-γ 
and IL-4, respectively, and their ability to 
impact other white blood cells, such as natural 
killer (NK) cells, dendritic cells and B cells (3-
5). NKT cells, specifically Type I NKT cells, 
have a semi-invariant T-cell antigen receptor 
(TCR) that has an evolutionarily conserved 
alpha chain, formed by a Vα14/Jα18 joining in 
mice and a homologous Vα24/Jα18 in humans 
(3). The TCR α chain, pairs with a less 
restricted β chain repertoire, to impart a 
specificity for glycosphingolipids (GSLs) 
presented by CD1d. CD1d is a member of the 
CD1 family of antigen presenting molecules 
(CD1a-e in humans, CD1d in mice) that is 
structurally similar to peptide presenting MHC 
class I antigen presenting molecules (6). The 
CD1d heavy chain is composed of three 
domains, α1, α2 and α3. While the α3 domain 
non-covalently associates with β2-
microglobulin, the α1-α2 superdomain forms a 
central, hydrophobic antigen binding groove 
(7). This groove further segregates into two 
connected pockets called A´ and F´. Each 
pocket binds one chain of a dual alkyl chain 
lipid antigen. In the case of GSLs, the 
sphingoid base binds in the F´ pocket, while 
the A´ pocket binds the fatty acid.  This lipid 
binding orientation allows the sugar head 
group to be exposed in the center for 
recognition by the Type I NKT cell TCR, with 
the α chain of the TCR providing the 
predominate binding energy (8,9). Many GSLs 
have been analyzed for the activation of Type 
I NKT cell TCRs, but the most commonly 
studied is α-galactosylceramide (αGalCer) 
(10,11). This prototypical glycolipid activates 
Type I NKT cells to secrete both IL-4 and 
IFN-γ in vivo within 90 minutes. Since this 
initial discovery, many glycolipids have been 
studied that sway the response of the immune 
system predominately towards either a Th1 or 
a Th2 response (12).  One of the earliest Th1 
skewing lipids studied to date is C-glycoside, 
in which the O-glycosidic linkage of αGalCer 
is replaced with a methylene group, known to 
stabilize this lipid (13). Although this lipid 
causes a pronounced Th1 response in mice, it 
is unable to activate human Type I NKT cells. 
The importance of Th1 skewing in a 
mammalian system is important for driving 
the system towards an inflammatory response 
essential for tumor clearance (14) and vaccine 
adjuvant activity (15). Thus Type I NKT cell 
lipids that stimulate IFN-γ have been studied 
in the context of possible therapeutic 
development. Although much work has been 
done to analyze these cytokine skewed 
responses, the exact mechanism of cytokine 
polarization is not completely elucidated. In 
this study, we selected 5 different lipids, 
previously demonstrated to activate Type I 
NKT cells, and tested their ability to activate 
human and mouse Type I NKT cells, side-by-
side. We have further assessed their TCR 
binding affinities and crystallized the mouse 
ternary CD1d-GSL-TCR complexes to 
analyze the molecular interactions that 
ultimately lead to TCR triggering. 
 
EXPERIMENTAL PROCEDURES 
GSL synthesis- The GSLs used in this study 
have all been described previously: EF77 (16), 
GCK127 and 152 (17), NC-αGC (18), 7DW8-
5 (19-23). 
 In vitro GSL presentation assays- 
The GSL cell free presentation assay has been 
described previously (24). 96-well plates were 
coated with 1 µg of CD1d and were incubated 
overnight with various concentrations of 
GSLs. The CD1d molecules were then co-
cultured with Type I NKT cell hybridomas 
overnight. The GSL cell based assay also has 
been described (25). Briefly, antigen 
presenting cells (APCs) (1×105 per well) were 
pulsed with 100 ng of the indicated lipid and 
were incubated overnight. The cells were then 
combined with 5×104  Vα14Vβ8.2 NKT cell 
hybridomas for 24 h. The DN3A4-1.2 (1.2) 
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Type I NKT hybridoma cell line has been 
described previously (26). TCR engagement 
was measured using a sandwich ELISA for IL-
2 cytokines in the supernatant of hybridoma 
cultures. 
 Human Type I NKT cell assay- The 
isolation and expansion of human Vα24+ NKT 
cell lines has been published previously (27). 
Human donor peripheral blood mononuclear 
cells (PBMCs, 1–1.5 ×106/ml) were isolated 
and cultured in RPMI 1640 (Invitrogen) 
supplemented with 10% v/v) FBS and 1% 
(v/v) Pen-Strep-Glutamine (10,000 U 
penicillin, 10,000 µg streptomycin, 29.2 
mg/ml L-glutamine; Invitrogen) and cultures 
were expanded by weekly re-stimulation with 
αGalCer-pulsed, irradiated PBMC and 
recombinant human IL-2. PBMCs (1×105 per 
well) were pulsed with GSLs and were seeded 
in 96 well plates and cultured in the presence 
of 5×104 Vα24+ human NKT cells for 24 h. 
GM-CSF release was evaluated in a sandwich 
ELISA following the manufacturer’s 
instructions (R&D Systems). 
 Mice- C57BL/6 were purchased from 
The Jackson Laboratory. All mice were 
housed in specific pathogen-free conditions 
and the experiments were approved by the 
Institutional Animal Care and Use Committee 
of the La Jolla Institute for Allergy & 
Immunology. Mice were injected with 1 µg of 
lipids intravenously and the sera of immunized 
mice were subjected to sandwich ELISAs to 
measure mouse IFN-γ levels. 
 Mouse and Human CD1d and TCR 
preparation- As reported previously (28), 
mouse CD1d-β2-microglobulin heterodimeric 
protein was expressed in a baculovirus 
expression system and human CD1d- β2-
microglobulin was prepared similarly to the 
mouse protein. The TCR was prepared by 
refolding as previously reported (29). 
 CD1d loading- Each GSL was 
dissolved in DMSO at a concentration of 1 or 
2 mg/mL. The individual GSLs were diluted 
in a vehicle solution (50 mM Tris-HCl pH 7.0, 
4.8 mg/ml sucrose, 0.5 mg/ml sodium 
deoxycholate and 0.022% Tween 20) and were 
incubated at 80° C for at least 20 minutes. The 
GSLs were then combined with CD1d protein 
in an approximate 3:1 molar ratio of lipid to 
protein overnight in the presence of 50 mM 
Tris-HCl pH 7.0.  
 SPR kinetic analysis- Biotinylated 
CD1d was processed and purified and studies 
were conducted using a Biacore 3000 (GE 
Healthcare) as reported previously (29) and 
lipid loading was done as described above. 
Following overnight GSL loading, 
approximately 300 response units of CD1d-
GSL complex were immobilized onto a 
streptavidin sensor chip surface by injecting 
the CD1d-GSL mixture at 5 µl/min using HBS 
(10 mM HEPES, 150 mM NaCl, 3.0 mM 
EDTA, pH 7.4) running buffer. A reference 
channel was bound with unloaded CD1d and 
increasing concentrations of refolded TCR 
were passed over at a flow rate of 30 µl/min. 
Kinetic association and dissociation curves 
were calculated using BIAevaluation software 
version 4.1. 
 Crystallization and structure 
determination- Following overnight GSL 
loading, the CD1d-GSL complexes were 
incubated with refolded TCR at room 
temperature for at least 30 minutes, followed 
by isolation of the complexes using Superdex 
S200 10/300 GL (GE Healthcare) equilibrated 
in buffer (50 mM Hepes pH 7.4, 150 mM 
NaCl). The isolated fractions containing the 
ternary complexes were concentrated and 
crystals were grown at 22.3°C by sitting drop 
vapor diffusion while mixing 0.5 µl protein 
solution with 0.5 µl precipitate. Precipitates 
were 0.2 M ammonium citrate dibasic pH 5.1 
20% PEG 4000 for EF77, 17% polyethylene 
glycol, 8% tascimate pH 4 for 7DW8-5, 20% 
polyethylene glycol, 0.2 M ammonium citrate 
dibasic for NC-αGC, 17% polyethylene 
glycol, 0.2 M potassium acetate for GCK127 
and 16% polyethylene glycol, 0.2 M 
ammonium citrate dibasic for GCK152. Single 
crystals were harvested and flash cooled in 
mother liquor containing 20% glycerol. 
Crystals were collected at the Stanford 
Synchrotron Radiation Lightsource and the 
Advanced Light Source and processed with 
the software Mosflm (30) or HKL2000 (31). 
The structures were solved by molecular 
replacement in CCP4 (Collaborative 
Computational Project, Number 4) (32). First, 
the coordinates for the CD1d protein of PDB 
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ID 2Q7Y were used, followed by the TCR 
coordinates of PDB ID 3QUZ.  Models were 
rebuilt into σA-weighted 2Fo – Fc and Fo – Fc 
difference electron density maps using COOT 
(33). The GSLs were built into 2Fo –Fc map 
and refined using REFMAC (34). Refmac 
geometric libraries for the glycolipids were 
obtained using the PRODRG server (35). Data 
collection and refinement statistics are 
summarized in Table 2.  
 
RESULTS 
Modifications of the αGalCer structure- We 
have compared the structure and antigenicity 
of αGalCer analogs modified in three different 
parts: the galactose headgroup, fatty acyl chain 
and the sphingoid base (Figure 1). In addition, 
GCK127 and GCK152 have their O-glycosidic 
linkages replaced with an E-alkene linker 
between the sugar and lipid moieties, 
reminiscent of C-glycoside (α-C-GalCer), 
while GCK152 also has a truncated fatty acid 
with a terminal phenyl group (C8-Ph) (17). 
Naphthylcarba-αGalCer (NC-αGC) has an 
aromatic 6”-OH galactose modification, 
similar to the previously crystalized 
naphthylurea (NU)-αGC. However, unlike 
NU-αGC where the naphthyl is linked via a 
urea group, NC-αGC has a carbamate linker, 
which provides more flexibility to the 
naphthyl moiety (18).  The rationale of 
introducing this flexible linker was to assess 
whether the rigidity of the urea linker or the 
aromatic nature and size of the naphthyl group 
cause the reported structural change in the A´ 
roof of CD1d (36). EF77 is a plakoside A-like 
glycolipid, a GSL isolated from the marine 
sponge, Plakortis simplex (37), and is related 
to the previously crystallized SMC124 lipid 
(16). The sugar head group and O-glycosidic 
linkage are identical to αGalCer but the acyl 
chain has been modified to mimic plakoside 
A, with a cyclopropyl group and double bond 
between carbons 4 and 5 (16). Like EF77, 
7DW8-5 also has a modification in the acyl 
group. The length of the chain has been 
shortened to 11 carbons and a parafluor-
phenyl group has been added (C11-Ph-F) 
(19,20). The rational behind those different 
modifications is that changes in the lipid 
moiety would be expected to mainly influence 
the lipid interaction with CD1d, while changes 
in the galactose moiety and linkage can affect 
interaction with CD1d, the TCR and they 
could confer resistance to endoglycosidases 
upon injection into mice, and thus could 
increase the half-life in serum. 
 Real-time TCR binding kinetics- First, 
we determined the TCR interactions of these 
lipids presented by both mouse and human 
CD1d using Surface Plasmon Resonance 
(SPR) (Figure 2). As has been seen previously, 
the affinity of the mouse TCR to the GSL-
CD1d complexes is higher (in the nM range) 
whereas the affinity of the human TCR for the 
GSL-CD1d complexes is weaker (in the µM 
range). According to the analysis using mouse 
CD1d and TCR (Figure 2A), the lipids cluster 
into a lower affinity and a higher affinity 
group. GCK127 (KD=247 ± 86 nM) and 
GCK152  (KD=197 ± 22 nM) show the lowest 
Vα14Vβ8.2 TCR affinity. This is similar to 
the affinity reported for the parent α-C-GalCer 
(KD=247 nM, (36), but approximately 10-fold 
weaker than αGalCer, which in our hands 
ranges in affinity from 11 to 25 nM (29,38). 
Of note, the binding affinity is still high 
compared to mouse TCR affinities for MHC 
presented peptides, which most often are in 
the micromolar range (39,40). The higher 
affinity group is comprised of the NC-αGC 
(KD=37.1 ± 14.10 nM), similar to NU-αGC 
(36), EF77 (44.7 ± 0.4 nM) and 7DW8-5  (94 
± 2.8 nM). The division into lower and higher 
affinity groups was not maintained in the SPR 
analysis using the human Vα24Vβ11 TCR and 
human CD1d (Figure 2B). GCK152 and EF77 
were the weakest binders with KD-values of 
6.85  ± 2.6 µM and 3.4 ± 2.71 µM, 
respectively. The other lipids had similar 
affinity to αGalCer, which in our hands ranges 
from 1-3 µM. GCK127 (1.45  ± 0.05 µM) and 
NC-αGC (1.45  ± 0.35 µM) were very similar 
and 7DW8-5 resulted in the highest TCR 
affinity (1.13  ± 0.9 µM). We noted that in the 
mouse studies the off-rate for the Type I NKT 
cell TCR for both GCK127 and GCK152 (kd 
=1.28 ± 0.0014 x 10-2 s−1 and 1.66 ± 0.0016 
x10-2 s−1, respectively) is 10x faster than the 
other ligands including αGalCer (kd= 2.2 ± 
0.52 x 10−3 s−1) (data not shown) but similar to 
α-C-GalCer (36). Therefore, we assume that 
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the GCK glycolipids were not able to induce 
the closure of the roof over the CD1d F’ 
pocket. As previously reported, some GSLs 
like αGalCer induce the formation of the F’ 
roof closure prior to TCR docking, through 
orienting CD1d side chains at L84, V149, and 
L150 to an optimal conformation for 
engagement by the TCR CDR3α residue L99. 
The pre-formed F’ roof closure has been 
correlated with a slower off-rate of the Type I 
NKT cell TCR (41). In the human SPR studies 
we noted that the off-rates for all the GSLs 
were similar, likely due to the inability of 
human CD1d to pre-form the closed F’ roof, 
as the L84 of mouse CD1d is altered to F84 in 
human CD1d and a fully closed F’ roof has 
not been observed in the hCD1d-αGalCer 
structure (42).  
 Crystal structures of the trimolecular 
complexes- In order to determine how each of 
these lipids is recognized by the TCR of Type 
I NKT cells, we crystallized each lipid in 
complex with mouse CD1d and the mouse Vα 
14Vβ8.2 TCR. Crystallographic parameters 
are listed in Table 2. The overall structures of 
all complexes were consistent with the 
previously crystallized CD1d-glycolipid-TCR 
complexes, with the TCR docked offset over 
the F´ pocket of CD1d in a parallel orientation 
to the two α helices (Figure 3), notably 
different from the diagonal footprint generated 
in MHC-peptide-TCR complexes. All GSLs 
bind with the fatty acid chain in the A´ pocket 
of CD1d, he sphingoid base nestles inside the 
F´ pocket and the galactose moiety exposed at 
the CD1d binding groove portal for TCR 
recognition.   Electron density for all of the 
lipids is well defined except for the acyl chain 
of 7DW8-5 (Figure 4). In this case, the 
electron density implies that the acyl chain can 
orient itself both clockwise and 
counterclockwise around cysteine 12 within 
the A’ binding pocket. Thus, we have modeled 
both acyl chain orientations of 7DW8-5 with 
50% occupancy (occurrence) (Figure 4F). 
 TCR-interactions- Previous studies 
established that the TCR of Type I NKT cells 
binds CD1d with a largely conserved binding 
footprint (43-46). Not surprisingly, the contact 
surfaces between CD1d and the TCR are very 
similar throughout the different ternary 
complexes (Table 2). All the TCR interactions 
with the antigen are formed with the 
conserved TCR α chain, while both TCR 
chains contact CD1d. TCR interactions with 
CD1d are dominated by the TCR α chain 
(818-870Å2 total buried surface area, BSA), 
but there is substantial involvement of the 
TCR β chain (582-650Å2 BSA) (Table 2). 
Contacts between TCRα and the ligand vary 
depending on the ligand modification, 
resulting in subtle differences in the 
presentation of the sugar to the TCR. Crystal 
structure analysis shows hydrogen bonding is 
maintained similar to αGalCer in the cases of 
7DW8-5, GCK127 and EF77, with contacts 
between the galactose and residues N30, R95 
and G96 of the Type I NKT TCR α chain 
(Figure 4). GCK152 shows the most deviation 
from this binding. It fails to maintain the 
hydrogen bonds between the 4” hydroxyl 
group and N30, and the 3” hydroxyl group and 
R95 of the TCR. Furthermore, it also fails to 
make a hydrogen bond between the 3’ 
sphingoid base hydroxyl group and D80 of the 
CD1d molecule. These differences likely 
partially account for its reduced TCR affinity. 
NC-αGC loses the hydrogen bond between the 
4” hydroxyl group of the sugar and N30 of the 
TCR (Figure 5C). It should be noted that due 
to the moderate resolution of the different 
complexes, a precise hydrogen-bond distance 
is not given and generally a cut-off of 
3.5Å distance is applied. Similarly to the 
previously crystallized NU-αGC, the naphthyl 
anchor binds within a newly formed pocket in 
the A’ roof of CD1d, slightly pulling the 
galactose away from the TCR. Although NC-
αGC was predicted to be more flexible than 
NU-αGC, when the two structures are 
overlayed (Figure 5F), there are no discernable 
differences between them at the resolution of 
this study, suggesting that the size and nature 
of the aromatic modification, and not the 
flexibility of the linker region, drives the 
induced fit observed in CD1d. We noted that 
the total buried surface area between the 
TCRα and GSL was highest in the group of 
three ligands with the highest TCR affinity, 
NC-αGC, EF77 and 7DW8-5 (Table 2). 
However, considering NC-αGC, the number 
of H-bonds between TCR and antigen did not 
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always correlate with the affinity, suggesting 
that van der Waals interactions can contribute 
greatly to the TCR binding affinity and can 
compensate for the loss of individual 
hydrogen bond interactions (Figure 5).  
Biological activity of the glycolipids- 
As all glycolipid antigens were bound by the 
TCR with moderate to high affinity, we 
investigated their activity in vitro and in vivo. 
Different biological assays for each of the 
glycolipids have been reported previously, 
EF77 (16), GCK127 and 152 (17), NC-αGC 
(18), 7DW8-5 (19-23), however, here we 
assess their potency side-by-side using the 
same assays.  First, we performed a cell-based 
antigen presentation assay, in which a mouse 
B-cell lymphoma cell line (A20) stably 
expressing CD1d was pulsed with various 
lipids and their ability to activate the mouse 
Vα14Vβ8.2 NKT cell hybridoma cell line 1.2 
was analyzed. TCR engagement and 
subsequent hybridoma activation was 
measured by IL-2 secretion. All the GSLs 
stimulated the hybridoma compared to the 
mock control, with 7DW8-5, EF77 and 
GCK152 giving the most potent response 
(Figure 6A).  
The ultimate goal for the synthesis of novel 
GSLs is to develop a possible therapeutic 
agent for human use. To address whether these 
lipids could activate human Type I NKT cells, 
we used a model whereby antigen-presenting 
cells in the form of PBMCs and Type I NKT 
cells were isolated from normal human donor 
blood samples. Various concentrations of 
lipids were added to PBMCs and activation of 
human Type I NKT cells was measured by 
GM-CSF cytokine secretion in the supernatant 
(one representative graph is shown, Figure 
6B). 7DW8-5, NC-αGC and EF77 are strong 
activators, capable of stimulating human Type 
I NKT cells in a dose-dependent manner.  
However, high concentrations of NC-αGC 
seemed to inhibit Type I NKT cell activation. 
In comparison, both alkene versions of the 
parental C-glycoside compound, GCK127 and 
GCK152, failed to activate human Type I 
NKT cells, even at high concentrations.  
We further tested the lipids in vivo by i.v. 
injection of 1 µg of each lipid into mice.  24 h 
post injection, we analyzed serum IFN-γ 
cytokine levels using a sandwich ELISA. NC-
αGC and EF77 were able to generate a 
pronounced, systemic IFN-γ burst at this 
timepoint (Figure 6C). To test whether the 
inability of the GCK compounds to show a 
strong response in any biological assay is due 
to unexpected degradation of the glycolipids 
during storage, we performed a cell free 
antigen presentation assay. Recombinant 
CD1d was coated in 96 well plates, incubated 
overnight with the indicated concentration of 
glycolipids and cultured with the Vα14Vβ8.2 
NKT cell hybridoma 1.2. We expected that 
glycolipids that result in a strong TCR binding 
affinity should also induce robust T cell 
hybridoma activation, since TCR triggering 
and subsequent T cell activation is 
independent of T cell co-stimulation. As such, 
we expected a correlation between TCR 
binding strength and cytokine production. 
Both GCK127 and GCK152 induced a robust 
IL-2 secretion, demonstrating that both lipids 
were still fully intact throughout the course of 
this study (Figure 6D). The same pattern was 
observed using a different Type I NKT cell 
hybridoma (data not shown). GCK127 and 
GCK152 induced a lower IL-2 production, 
compared to 7DW8-5 and EF77, in correlating 
with their lower TCR affinity. However, 
surprisingly, NC-αGC, which had the highest 
TCR affinity, gave the lowest response.  
In summary, we measured the 
formation of the trimolecular complex of 
CD1d, GSL antigen and the TCR by SPR and 
analyzed the nature of the molecular 
interactions by X-ray crystallography.    This 
analysis provided insights into the ways these 
antigens can be bound and recognized.  
Differences in TCR affinity and binding 
kinetics were not highly predictive even of the 
ability of the compounds to stimulate Type I 
NKT cell hybridomas in a cell-free antigen 
presentation assay. They were less predictive 
of the ability to stimulate Type I NKT cell 
cytokine responses in vivo.  Therefore, other 
properties, including solubility, interactions 
with lipid binding proteins, uptake by different 
cell types and chemical stability of each lipid 
appear to affect stimulation of Type I NKT 
cells. While NC-αGC is not able to activate 
Type I NKT cells when pulsed into A20 cells, 
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it strongly activates human Type I NKT cells 
using pulsed PBMCs and murine Type I NKT 
cells when injected intravenously into mice. In 
contrast, 7DW8-5 potently activates human 
Type I NKT cells and murine Type I NKT cell 
hybridomas using pulsed A20 cells but not 
when injected intravenously. EF77 was the 
only lipid that gave strong responses in all 
three assays, while the GCK series failed to 
give a robust response in vivo or in cell based 
assays, even though the TCR binding kinetics 
were among the strongest for human Type I 
NKT cells (Figure 2). 
   
 
DISCUSSION 
 Many Type I NKT cell activating 
GSLs have been assessed to determine how 
they stimulate the human and mouse immune 
systems (12). Analysis of GSLs reported to be 
Th1 skewing clearly indicate that a variety of 
parameters are in play that will determine the 
in vivo immune response in mice and humans, 
and potency cannot be predicted by a purely 
biochemical approach or by any one type of 
assay. As mouse and human Type I NKT cells 
have different fine specificities for CD1d 
presented antigens, structural studies of the 
human complexes are important to dissect the 
underlying structural differences (47). 
However, we were unsuccessful to obtain the 
required resolution for robust structure 
determination using the human molecules.  
Instead, biochemical approaches can yield 
important insights into the mechanism that 
governs the binding reaction and they can 
contribute to the design of even more effective 
stimulators of Type I NKT cells.  For 
example, it is interesting to note that although 
the linker of NU-αGC has been altered in the 
NC-αGC lipid, allowing for more flexibility of 
the naphthyl group, the two crystal structures 
show no obvious differences and the overlay 
indicates the conserved binding orientation of 
the Type I NKT cell TCR trumps flexibility in 
these models. NC-αGC is a very strong 
antigen in vivo in mice and in vitro for 
humans. Although it lacks activity in the in 
vitro cell presentation assay, we hypothesize 
that this may reflect reduced in vitro CD1d 
loading efficiency, due to the aromatic naphtyl 
moiety, which reduces water solubility, or 
possibly the absence of a crucial lipid binding 
or transport protein derived from the APCs, 
subsequently leading to less stimulatory CD1d 
molecules and thus less T cell activation. 
Conversely, EF77, the plakoside A GSL, 
demonstrates potent activity in all assays. 
7DW8-5 activates mouse and human Type I 
NKT cells in vitro in the presence of APCs, 
and the ability of 7DW8-5 to activate human 
Type I NKT cells correlates with previously 
reported data that this GSL is able to serve as 
a vaccine adjuvant in primate models. 
Although this GSL does not cause robust IFN-
γ cytokine secretion in our mouse in vivo 
system, this could be due to the fact that this 
lipid may biodistribute differently than other 
GSLs after i.v. injection, perhaps a different 
route is used in primates. It has been noted 
that mouse intramuscular injection of this lipid 
causes it to localize to local lymph nodes 
whereas αGalCer seems to go systemic 
(Moriya Tsuji, personal communication).  The 
EF77 crystal structure showed similar features 
to its sister ligand SMC124. Both are related 
to plakoside A, but the EF77 ceramide has an 
αGalCer-like sphingosine  and the plakoside 
A alkyl chain. The plakoside A acyl chain, 
with its cyclopropyl group, binds in the 
hydrophobic A’ pocket of CD1d.  SMC124 
has the opposite configuration, with an 
αGalCer acyl chain and the plakoside A 
sphingoid base, which also has a cyclopropyl 
group, buried in the F’ pocket (16). Similar to 
EF77, the acyl chain modified 7DW8-5 ligand 
shows the phenyl ring localizing to the A’ 
groove, however, this GSL proved more 
difficult to model. Our crystal structure shows 
a duel binding motif of the acyl chain in the 
A’ pocket indicating that the fatty acid chain 
may orient both clockwise and 
counterclockwise around C12, possibly 
altering its interaction with CD1d, rather than 
the TCR. 
 The GCK127 and GCK152 have the 
weakest affinity in the mouse SPR studies, 
with rapid off-rates, which may be in part due 
to the inability of the CD1d F’ roof to pre-
form prior to TCR engagement (48). This F’ 
roof formation likely occurs upon binding of 
the other GSLs used in this study, accounting 
Effects of αGalCer Structural Modifications	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for the 10-fold difference in dissociation rates 
in the mouse SPR studies. Because this pre-
formation does not occur in human CD1d, we 
do not see a disparity in the dissociation rates 
of the human Type I NKT cell TCR. The 
GCK152 GSL also seems to fail to form some 
of the hydrogen bonds seen between αGalCer 
and CD1d and TCR, also accounting for a 
faster off-rate of the TCR. Although the 
human TCR affinities would predict a human 
Type I NKT cell response, GCK127 and 
GCK152 do not strongly activate the human 
cell lines in our hands similar to what was 
observed for the related α-C-GalCer. It is 
perhaps this alteration from an O-glycoside 
bond to a carbon linkage that slightly alters the 
binding of the glycolipid within CD1d. A 
rotation of the 3’-OH of the sphingoid base 
followed by concomitant loss of a hydrogen 
bond with Asp80 of CD1d has been observed 
in two separate crystal structures (36,49). 
Nonetheless, lipids of this nature do not 
appear to exhibit the same therapeutic 
potential than the other lipids in our assays. 
The buried surface area contacts between the 
TCRα loop and CD1d may shed some light on 
the variation in the biological and biochemical 
parameters. In conclusion, these different 
GSLs have the capacity to form interactions 
between CD1d and Type I NKT cells, but 
have various responses in the mouse and 
human studies, indicating a lack of one-to-one 
correlation.  
Recent studies suggested that kinetic 
data obtained from TCR and peptide-MHC 
molecules in solution (e.g. by SPR), do not 
always correlate with T cell signaling outcome 
(50). Instead, measuring the interaction in 2D, 
where both MHC and TCR are each presented 
on a cell is a better predictor of the potency of 
an antigen. In the 2D system, a pulling force 
can be applied to mimic naturally occurring 
forces that occur when cells are in contact. 
Under those conditions, the TCR dissociation 
is 3-4 orders of magnitude increase compared 
to measurements carried out in solution 
(50,51). Applying these forces to the CD1d 
system would allow us to assess the role of the 
CD1d-lipid interaction in modulating the 
overall stability of the ternary complex, as 
interactions among all three molecules 
(antigen-CD1d, antigen-TCR, and CD1d-
TCR) are likely important in the 2D system. 
When performing SPR studies, the stability of 
the CD1d-lipid complex does not affect TCR 
affinity, likely because no pulling forces are 
applied. Future studies could include the study 
of the 2D interaction using pulling force, 
while systematically changing the terminal 
lipid backbone, to alter its interaction with 
CD1d (50). Those assays would shed light on 
the contribution of the CD1d-lipid interaction 
in T cell triggering through modulating the 
stability and duration of their interaction. In 
addition, future studies that can accurately 
measure the pharmacokinetic properties of the 
GSLs, binding affinities for the GSL (see 
above) and CD1d molecules and 
biodistribution of different GSLs would be 
particularly interesting to address this 
outstanding issue.  
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FIGURE LEGENDS: 
 
FIGURE 1. Chemical structures of glycosphingolipids. In green, the carbohydrate galactose 
sugar moiety, in red the fatty acid chain and in blue, the sphingoid base of αGalCer. In yellow, 
structural modifications of each GSL compared to the αGalCer template structure. 
 
FIGURE 2. Real-time TCR binding kinetics. Binding of refolded mouse Vα14Vβ8.2 TCR (A) 
or human Vα24Vβ11 TCR (B) to the indicated glycolipids presented by mouse and human CD1d, 
respectively. One representative sensorgram is depicted at the bottom showing the binding 
response of increasing concentrations of TCR (colored curves) and the calculated fit (black 
curves). 
 
FIGURE 3. Ternary crystal structures of mouse CD1d-GSL- Vα14Vβ8.2 NKT cell TCR 
complexes. A. GCK152 B.GCK127 C. NC-αGC D. 7DW8-5 E. EF77. CD1d in grey, β2M in 
blue. TCRα chain in cyan and TCRβ chain in orange. 
 
FIGURE 4. Electron Density of GSLs shown with CD1d. Note: α2 helix removed for clarity 
A. NC-αGC B. EF77 C. 7DW8-5 D. GCK152 E. GCK127 F. dual binding motif for acyl chain of 
7DW8-5. 2FoFc electron density is drawn as a blue mesh around the glycolipid (colored sticks) 
and contoured at 1σ. CD1d in grey 
 
FIGURE 5. Mouse Vα14Vβ8.2 NKT cell TCR hydrogen bond interactions with CD1d and 
GSLs A. GCK127 B. GCK152 C.NC-αGC D. 7DW8-5 E. EF77 F. Overlay of NC-αGC (cyan) 
with NU-αGC (purple) ribbon crystal structures. Hydrogen bonds between TCRα (in cyan) and 
the various glycolipids (colored sticks) are indicated by blue dashed lines. Individual OH groups 
of the galactose sugar that participate in hydrogen bonding are labeled with position. CD1d α1-
helix as a reference shown in grey. 
 
FIGURE 6. Biological Assays with GSLs A. Cell based assay in which an A20 B cell 
lymphoma cell line transfected with CD1d was pulsed with 100 ng of the indicated GSL and co-
cultured with a Vα14Vβ8.2 NKT cell hybridoma (1.2). TCR engagement measured after 24 
hours through IL-2 production in serum measured with a sandwich ELISA. Data represents 
samples in triplicate and is representative of three independent experiments. B. Human Type I 
NKT cells were activated by human PBMCs pulsed with the indicated glycolipid concentrations 
24 h. Cytokine levels for human GM-CSF were measured in the supernatant using a sandwich 
ELISA assay. Representative data from one of two experiments performed in triplicate wells 
using multiple human cell lines are shown. C. C57Bl/6 mice were injected with 1 µg of the 
indicated GSL, and sera were analyzed at 24 hours. Serum samples were measured for IFN-γ 
cytokine levels by ELISA. Data are representative of 2 independent experiments of 3 mice per 
group. Error bars represent ± SEM. D. Cell free antigen presentation assay. 96 well plates were 
coated with recombinant CD1d and incubated overnight with indicated concentration of 
glycolipids. After the initial incubation, Vα14Vβ8.2 NKT cell hybridoma 1.2 was added 
overnight. Serum IL-2 was measured using a sandwich ELISA. Representative data from 1 of 2 
different hybridoma lines are shown. 
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TABLES 	  
TABLE 1. Refinement statistics for the CD1d-GSL-TCR complexes 
Data 
collection 
statistics 
CD1d-
GCK127-
TCR 
CD1d-
GCK152-
TCR 
CD1d-
NC-αGC-
TCR 
CD1d-
EF77-
TCR 
CD1d-
7DW8-5-
TCR 
PDB ID 4Y4F 4Y4H 4Y16 4Y4K 4Y2D 
Space group P21 P21 C2221 C2221 P21 
Cell dimension           
       a, b, c, (Å) 
78.6, 
149.7, 
101.4 
79.4, 
150.4, 
102.5 
79.6, 
191.9, 
151.9 
79.1, 
191.4, 
151.3 
79.4, 
150.3, 
100.8 
       α, β, γ (°) 90, 96.5,90 
90, 96.4, 
90 
90, 90, 
90 
90, 90, 
90 
90, 96.2, 
90 
Resolution 
range (Å) 
[outer shell] 40-3.2 [3.31-3.2] 
40-3.1 
[3.15-3.1] 
66.21-
2.60 
[2.71-
2.60] 
95.7-2.9 
[3.06-2.9] 
500-3.05 
[3.12-
3.05] 
No. reflections 38,286 42,694 34,681 25,092 44,418 
            
Rmerge (%) 13 [63.9] 
11.3 
[59.9] 
10.3 
[47.8] 
17.2 
[59.4] 9.3 [53.6] 
Rpim (%) n/a n/a 7.0 [32.6] 
11.1 
[38.4] n/a 
Multiplicity 3.3 [3.3] 3.8 [4.0] 2.9 [2.9] 3.2 [3.4] 3.0 [3.0] 
Average I/sI 13.7 [2.1] 21.5 [2.7] 6.8 [2.3] 5.9 [2.2] 13.2 [2.0] 
Completeness 
(%) 
98.2 
[91.1] 
99.4 
[100] 
96.2 
[95.7] 
97.4 
[99.1] 
99.3 
[99.8] 
            
Refinement 
statistics           
No. atoms 12,599 12,469 6,532 6,305 11,943 
       Protein 12,389 12,247 6,333 6,183 11,627 
       Ligand  126 96 73 56 208 
       
Carbohydrate 84 126 80 66 108 
Water 0 0 46 0 0 
R/Rfree (%) 21.8/25.7 24.2/28.3 21.1/24.4 21.9/26.5 21.7/25.7 
Ramachandran 
plot (%)           
       Favored  96.91 95.52 96.36 96.11 95.93 
       Allowed  99.75 99.68 100 99.75 99.87 
R.m.s. 
deviations           
       Bonds (Å) 0.006 0.01 0.01 0.005 0.005 
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       Angles (°) 0.879 1.226 1.248 1.076 0.994 
B-factors (Å2)           
       Protein  89.25 75.42 41.75 37.58 75.66 
       Ligand  67.87 58.88 33.77 28 50.79 
       
Carbohydrate  83.86 87.85 54.56 44.54 96.54 
 
 
 
TABLE 2. Total Buried surface areas between mouse TCR-CD1d and TCRα-glycolipid 
(in Å3) 
  CD1d-ligand-TCR complex 
Contact surfaces GCK127 GCK152 NC-αGC EF77 7DW8-5 
TCRα-ligand 298 290 298 303 241 
TCRα-CD1d 844 818 867 854 870 
TCRβ-CD1d 610 647  633 637 582 
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FIGURES 
Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5
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Figure 6 
 
 
 
 
 
